Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
AssigneeRamot at Tel-Aviv University Ltd.
InventorsBernard Attali, Asher Peretz
Life of this patent
Estimating the term…
Abstract
Compounds, compositions and methods are provided which are useful in the treatment of conditions such as central or peripheral nervous system disorders through the modulation of potassium ion flux through voltage-dependent potassium channels and/or depressing cortical and/or peripheral neuron activity are disclosed. Novel derivatives of N-phenylanthranilic acid are also disclosed.
Claims15
A method of modulating a voltage-dependent potassium channel, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound having a general Formula I:
- wherein:
- Z is an A-G(=K)—X—Y group,
- and wherein:
- A is alkyl or absent;
- G is C;
- K is selected from the group consisting of O and S;
- X is selected from the group consisting of O and NRb;
- and
- Y is selected from the group consisting of hydroxyalkyl and a polyalkylene glycol residue,
- R1 is selected from the group consisting of hydrogen, alkyl, cycloalkyl or aryl;
- each of R2, R3, R4, R5, R6, R7, R8, R9 and R10 is independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, cyano, nitro, amino and —NR15R16, or, alternatively, at least two of R2, R3, R4, R5 and R6, of R7, R8, R9 and R10 form a five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring;
- R15 and R16 are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, carbonyl and sulfonyl, or, alternatively R15 and R16 form a five- or six-member heteroalicyclic ring;
- and
- Rb is selected from the group consisting of hydrogen, alkyl, cycloalkyl and aryl,
- wherein said modulating of said voltage-dependent potassium channel is for a treatment of a condition or disorder selected from the group consisting of epilepsy, and schizophrenia.
A method of treating a neuropathic pain, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound having general Formula I:
- wherein:
- Z is an A-G(=K)—X—Y group,
- and wherein:
- A is alkyl or absent;
- G is selected from the group consisting of C, S and PRa;
- K is selected from the group consisting of O and S;
- X is selected from the group consisting of O, S and NRb or absent;
- and
- Y is selected from the group consisting of hydroxyalkyl and a polyalkylene glycol residue,
- R1 is selected from the group consisting of hydrogen, alkyl, cycloalkyl or aryl;
- each of R2, R3, R4, R5, R6, R7, R8, R9 and R10 is independently selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, cyano, nitro, amino and —NR15R16, or, alternatively, at least two of R2, R3, R4, R5 and R6, and/or of R7, R8, R9 and R10 form a five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring;
- R15 and R16 are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, carbonyl and sulfonyl, or, alternatively R15 and R16 form a five- or six-member heteroalicyclic ring;
- and
- each of Ra and Rb is selected from the group consisting of hydrogen, alkyl, cycloalkyl and aryl.
Dependencies are inferred from the claim text.